Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | TDO2 | P48775 | 3/20 | 0.52 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27793513 | 1.00 | ACP3 (0.53) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL29609159 | 1.00 | ACP3 (0.53) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL477602 | 1.00 | ACP3 (0.53) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL11641801 | 0.88 | ESR2 (0.46) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL4082510 | 0.87 | TSHR (0.58) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL30986710 | 0.87 | TSHR (0.58) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL29976363 | 0.85 | ADRB2 (0.48) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL230382 | 0.85 | ADRB2 (0.48) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL477355 | 0.85 | IDO1 (0.54) | ACP3IDO1TDO2IDO2MAPT | |
| SCHEMBL5753910 | 0.84 | IGF1R (0.43) | ACP3IDO1TDO2IDO2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333985-B1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240262814-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4333985-A1 | MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023047107-A1 | ARYL OR HETEROARYL DERIVED COMPOUNDS FOR THE TREATMENTS OF MICROBIAL INFECTIONS | THE UNIVERSITY OF DURHAM (GB) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022235725-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| EP-0894794-A1 | Optical isomers of cloperastine | AESCULAPIUS FARMACEUTICI S.r.l. (IT) | 1999-02-03 | — | — | EP | disclosed |
| EP-0385491-A1 | Optically active isomer of cloperastine possessing antitussive activity, a process for its preparation and pharmaceutical compositions which contain it | MAGIS FARMACEUTICI S.p.A. (IT) | 1990-09-05 | — | — | EP | disclosed |
| US-4175945-A | PLANT GROWTH REGULATORS FOR TABACCO | ROHM AND HAAS COMPANY (US) | 1979-11-27 | — | — | US | disclosed |
| US-4138488-A | Diphenylmethyl picolinic acid derivatives and their use as anti-acne agents | SCHERING CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
| US-4120687-A | CONTROLLING GROWTH OF TOBACCO SUCKERS | MEISINGER ROBERT H | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACP3 1293/4885IDO1 1773/4885TDO2 3317/4885 |
| US-20240262814-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | ACP3 2313/4885IDO1 4412/4885TDO2 4479/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACP3 1293/4885IDO1 1773/4885TDO2 3317/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | ACP3 1480/4885IDO1 292/4885TDO2 364/4885 |
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | ACP3 4636/4885IDO1 953/4885TDO2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.